San Diego, CA (PRWEB) August 30, 2014
According to Bloomberg, U.S. District Judge Rebecca Doherty upheld a decision that requires Takeda Pharmaceutical Co. and Eli Lilly & Co. to pay $9 billion in punitive damages for claims that the drugmakers concealed information about a risk of bladder cancer associated with the diabetes medication Actos. The case, Allen v. Takeda Pharmaceuticals North America Inc. (12-cv-00064), was filed in the U.S. District Court, Western District of Louisiana (Lafayette).*
According to Bloomberg, Takeda and Lilly disagree with the ruling and are awaiting a motion for a new trial. On Aug. 27, Doherty ruled that the jurors properly considered evidence showing the defendant companies failed to properly warn healthcare providers and Actos patients about the risk of bladder cancer.*
“We agree with the ruling and believe that it sets the tone for similar lawsuits,” said Melinda Helbock, Founder of The Law Office of Melinda J. Helbock A.P.C. “The claims that Takeda and Eli Lilly failed to warn patients and doctors about the potential risk for bladder cancer when using Actos are similar to those of our clients and we are pleased to see the litigation moving forward.”
In light of the recent ruling, The Law Office of Melinda J. Helbock A.P.C. announces that it continues to investigate potential claims on behalf of individuals who have taken Actos and have been diagnosed with bladder cancer. “We represent individuals who believe they have suffered injury or loss due to the adverse effects of medications and the negligent actions of pharmaceutical companies,” said Helbock.
Actos is prescribed for the treatment of type 2 diabetes.
The Law Office of Melinda J. Helbock A.P.C. is a San Diego based personal injury law firm, committed to helping individuals and families harmed by negligence. For more information about the firm, please visit our website.